Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related Comorbidities

Next Previous
Trial Profile

A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related Comorbidities

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 22 Nov 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Retatrutide (Primary)
  • Indications Obesity
  • Focus Therapeutic Use
  • Sponsors Eli Lilly and Company

Most Recent Events

  • 02 Sep 2024 Results assessing the effects of RETA on the serum lipid profile we analyzed changes in apolipoprotein levels and distribution and size of lipoprotein particlespresented at the ESC Congress 2024 - Annual Congress of the European Society of Cardiology
  • 01 Jul 2024 Results assessing efficacy of retatrutide for metabolic dysfunction-associated steatotic liver disease published in the Nature Medicine
  • 14 Nov 2023 Results (n=98) assessing effects of RETA on liver fat (LF) and correlations with metabolic measures in subjects with MASLD included in this trial assessing effects of RETA on liver fat (LF) and correlations with metabolic measures in subjects with MASLD presented at The Liver Meeting 2023: 74th Annual Meeting of the American Association for the Study of Liver Diseases

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top